GrippeEspagneV1, Main, Exploration, bibRecord, 000134

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.

Identifieur interne : 000134 ( Main/Exploration ); précédent : 000133; suivant : 000135

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.

Auteurs : M. Rondy [France] ; J. Castilla [Espagne] ; O. Launay [France] ; S. Costanzo [Italie] ; C. Ezpeleta [Espagne] ; F. Galtier [France] ; K. De Gaetano Donati [Italie] ; A. Moren [France]

Source :

Human vaccines & immunotherapeutics [ 2164-554X ] ; 2016.

RBID : pubmed:27065000

Descripteurs français

KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Espagne (MeSH), Femelle (MeSH), France (MeSH), Grippe humaine (diagnostic), Grippe humaine (prévention et contrôle), Grippe humaine (virologie), Hospitalisation (statistiques et données numériques), Humains (MeSH), Italie (MeSH), Jeune adulte (MeSH), Modèles logistiques (MeSH), Mâle (MeSH), Saisons (MeSH), Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (isolement et purification), Sous-type H3N2 du virus de la grippe A (génétique), Sous-type H3N2 du virus de la grippe A (isolement et purification), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Surveillance sentinelle (MeSH), Union européenne (MeSH), Vaccination (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Études cas-témoins (MeSH).
MESH :
- administration et posologie : Vaccins antigrippaux.
- diagnostic : Grippe humaine.
- génétique : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
- immunologie : Vaccins antigrippaux.
- isolement et purification : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Hospitalisation.
- virologie : Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Espagne, Femelle, France, Humains, Italie, Jeune adulte, Modèles logistiques, Mâle, Saisons, Sujet âgé, Sujet âgé de 80 ans ou plus, Surveillance sentinelle, Union européenne, Vaccination, Études cas-témoins.
Wicri :
- geographic : France, Italie, Espagne.

English descriptors

KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Case-Control Studies (MeSH), European Union (MeSH), Female (MeSH), France (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza A Virus, H3N2 Subtype (genetics), Influenza A Virus, H3N2 Subtype (isolation & purification), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (diagnosis), Influenza, Human (prevention & control), Influenza, Human (virology), Italy (MeSH), Logistic Models (MeSH), Male (MeSH), Middle Aged (MeSH), Outcome Assessment, Health Care (MeSH), Seasons (MeSH), Sentinel Surveillance (MeSH), Spain (MeSH), Vaccination (MeSH), Young Adult (MeSH).
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- geographic : France, Italy, Spain.
- diagnosis : Influenza, Human.
- genetics : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- isolation & purification : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- prevention & control : Influenza, Human.
- statistics & numerical data : Hospitalization.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, European Union, Female, Humans, Logistic Models, Male, Middle Aged, Outcome Assessment, Health Care, Seasons, Sentinel Surveillance, Vaccination, Young Adult.

Abstract

We conducted a multicentre test negative case control study to estimate the 2013-14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: -1.9;85.4), 39.4% (95%CI: -32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18-64, 65-79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: -145.3;65.4), 25.6% (95%CI: -36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18-64, 65-79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013-14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.

DOI: 10.1080/21645515.2015.1126013
PubMed: 27065000
PubMed Central: PMC5036960

Affiliations:

Espagne, France, Italie

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 00137
to stream Main, to step Curation: 000137

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.</title>
<author><name sortKey="Rondy, M" sort="Rondy, M" uniqKey="Rondy M" first="M" last="Rondy">M. Rondy</name>
<affiliation wicri:level="1"><nlm:affiliation>a Epicon0063ept , Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>a Epicon0063ept , Paris </wicri:regionArea>
<wicri:noRegion>Paris </wicri:noRegion>
<wicri:noRegion>Paris </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Castilla, J" sort="Castilla, J" uniqKey="Castilla J" first="J" last="Castilla">J. Castilla</name>
<affiliation wicri:level="1"><nlm:affiliation>b Instituto de Salud Pública de Navarra, IdiSNA, CIBER Epidemiología y Salud Pública , Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>b Instituto de Salud Pública de Navarra, IdiSNA, CIBER Epidemiología y Salud Pública </wicri:regionArea>
<wicri:noRegion>CIBER Epidemiología y Salud Pública </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Launay, O" sort="Launay, O" uniqKey="Launay O" first="O" last="Launay">O. Launay</name>
<affiliation wicri:level="1"><nlm:affiliation>c Inserm, CIC 1417 and F-CRIN, Innovative clinical research network in vaccinologie (I-REIVAC), Université Paris Descartes; Sorbonne Paris Cité ; Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>c Inserm, CIC 1417 and F-CRIN, Innovative clinical research network in vaccinologie (I-REIVAC), Université Paris Descartes; Sorbonne Paris Cité ; Paris </wicri:regionArea>
<wicri:noRegion>Université Paris Descartes; Sorbonne Paris Cité ; Paris </wicri:noRegion>
<wicri:noRegion>Université Paris Descartes; Sorbonne Paris Cité ; Paris </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Costanzo, S" sort="Costanzo, S" uniqKey="Costanzo S" first="S" last="Costanzo">S. Costanzo</name>
<affiliation wicri:level="1"><nlm:affiliation>d Department of Epidemiology and Prevention , IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) , Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>d Department of Epidemiology and Prevention , IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) </wicri:regionArea>
<wicri:noRegion>Pozzilli (Isernia) </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ezpeleta, C" sort="Ezpeleta, C" uniqKey="Ezpeleta C" first="C" last="Ezpeleta">C. Ezpeleta</name>
<affiliation wicri:level="1"><nlm:affiliation>e Service of Clinical Microbiology, Complejo Hospitalario de Navarra, IdiSNA , Pamplona , Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>e Service of Clinical Microbiology, Complejo Hospitalario de Navarra, IdiSNA , Pamplona </wicri:regionArea>
<wicri:noRegion>Pamplona </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Galtier, F" sort="Galtier, F" uniqKey="Galtier F" first="F" last="Galtier">F. Galtier</name>
<affiliation wicri:level="1"><nlm:affiliation>f CHRU de Montpellier, Inserm, CIC 1411 and REIVAC , Montpellier , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>f CHRU de Montpellier, Inserm, CIC 1411 and REIVAC , Montpellier </wicri:regionArea>
<wicri:noRegion>Montpellier </wicri:noRegion>
<wicri:noRegion>Montpellier </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Gaetano Donati, K" sort="De Gaetano Donati, K" uniqKey="De Gaetano Donati K" first="K" last="De Gaetano Donati">K. De Gaetano Donati</name>
<affiliation wicri:level="1"><nlm:affiliation>g Department of Infectious Disease , Catholic University , Rome , Italy .</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>g Department of Infectious Disease , Catholic University , Rome </wicri:regionArea>
<wicri:noRegion>Rome </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moren, A" sort="Moren, A" uniqKey="Moren A" first="A" last="Moren">A. Moren</name>
<affiliation wicri:level="1"><nlm:affiliation>a Epicon0063ept , Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>a Epicon0063ept , Paris </wicri:regionArea>
<wicri:noRegion>Paris </wicri:noRegion>
<wicri:noRegion>Paris </wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27065000</idno>
<idno type="pmid">27065000</idno>
<idno type="pmc">PMC5036960</idno>
<idno type="doi">10.1080/21645515.2015.1126013</idno>
<idno type="wicri:Area/Main/Corpus">00137</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00137</idno>
<idno type="wicri:Area/Main/Curation">000137</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000137</idno>
<idno type="wicri:Area/Main/Exploration">000137</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.</title>
<author><name sortKey="Rondy, M" sort="Rondy, M" uniqKey="Rondy M" first="M" last="Rondy">M. Rondy</name>
<affiliation wicri:level="1"><nlm:affiliation>a Epicon0063ept , Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>a Epicon0063ept , Paris </wicri:regionArea>
<wicri:noRegion>Paris </wicri:noRegion>
<wicri:noRegion>Paris </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Castilla, J" sort="Castilla, J" uniqKey="Castilla J" first="J" last="Castilla">J. Castilla</name>
<affiliation wicri:level="1"><nlm:affiliation>b Instituto de Salud Pública de Navarra, IdiSNA, CIBER Epidemiología y Salud Pública , Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>b Instituto de Salud Pública de Navarra, IdiSNA, CIBER Epidemiología y Salud Pública </wicri:regionArea>
<wicri:noRegion>CIBER Epidemiología y Salud Pública </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Launay, O" sort="Launay, O" uniqKey="Launay O" first="O" last="Launay">O. Launay</name>
<affiliation wicri:level="1"><nlm:affiliation>c Inserm, CIC 1417 and F-CRIN, Innovative clinical research network in vaccinologie (I-REIVAC), Université Paris Descartes; Sorbonne Paris Cité ; Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>c Inserm, CIC 1417 and F-CRIN, Innovative clinical research network in vaccinologie (I-REIVAC), Université Paris Descartes; Sorbonne Paris Cité ; Paris </wicri:regionArea>
<wicri:noRegion>Université Paris Descartes; Sorbonne Paris Cité ; Paris </wicri:noRegion>
<wicri:noRegion>Université Paris Descartes; Sorbonne Paris Cité ; Paris </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Costanzo, S" sort="Costanzo, S" uniqKey="Costanzo S" first="S" last="Costanzo">S. Costanzo</name>
<affiliation wicri:level="1"><nlm:affiliation>d Department of Epidemiology and Prevention , IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) , Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>d Department of Epidemiology and Prevention , IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) </wicri:regionArea>
<wicri:noRegion>Pozzilli (Isernia) </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ezpeleta, C" sort="Ezpeleta, C" uniqKey="Ezpeleta C" first="C" last="Ezpeleta">C. Ezpeleta</name>
<affiliation wicri:level="1"><nlm:affiliation>e Service of Clinical Microbiology, Complejo Hospitalario de Navarra, IdiSNA , Pamplona , Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>e Service of Clinical Microbiology, Complejo Hospitalario de Navarra, IdiSNA , Pamplona </wicri:regionArea>
<wicri:noRegion>Pamplona </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Galtier, F" sort="Galtier, F" uniqKey="Galtier F" first="F" last="Galtier">F. Galtier</name>
<affiliation wicri:level="1"><nlm:affiliation>f CHRU de Montpellier, Inserm, CIC 1411 and REIVAC , Montpellier , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>f CHRU de Montpellier, Inserm, CIC 1411 and REIVAC , Montpellier </wicri:regionArea>
<wicri:noRegion>Montpellier </wicri:noRegion>
<wicri:noRegion>Montpellier </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Gaetano Donati, K" sort="De Gaetano Donati, K" uniqKey="De Gaetano Donati K" first="K" last="De Gaetano Donati">K. De Gaetano Donati</name>
<affiliation wicri:level="1"><nlm:affiliation>g Department of Infectious Disease , Catholic University , Rome , Italy .</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>g Department of Infectious Disease , Catholic University , Rome </wicri:regionArea>
<wicri:noRegion>Rome </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moren, A" sort="Moren, A" uniqKey="Moren A" first="A" last="Moren">A. Moren</name>
<affiliation wicri:level="1"><nlm:affiliation>a Epicon0063ept , Paris , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>a Epicon0063ept , Paris </wicri:regionArea>
<wicri:noRegion>Paris </wicri:noRegion>
<wicri:noRegion>Paris </wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Human vaccines & immunotherapeutics</title>
<idno type="eISSN">2164-554X</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Case-Control Studies (MeSH)</term>
<term>European Union (MeSH)</term>
<term>Female (MeSH)</term>
<term>France (MeSH)</term>
<term>Hospitalization (statistics & numerical data)</term>
<term>Humans (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term>
<term>Influenza A Virus, H3N2 Subtype (genetics)</term>
<term>Influenza A Virus, H3N2 Subtype (isolation & purification)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (diagnosis)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Italy (MeSH)</term>
<term>Logistic Models (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Outcome Assessment, Health Care (MeSH)</term>
<term>Seasons (MeSH)</term>
<term>Sentinel Surveillance (MeSH)</term>
<term>Spain (MeSH)</term>
<term>Vaccination (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Espagne (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>France (MeSH)</term>
<term>Grippe humaine (diagnostic)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Grippe humaine (virologie)</term>
<term>Hospitalisation (statistiques et données numériques)</term>
<term>Humains (MeSH)</term>
<term>Italie (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Modèles logistiques (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Saisons (MeSH)</term>
<term>Sous-type H1N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term>
<term>Sous-type H3N2 du virus de la grippe A (génétique)</term>
<term>Sous-type H3N2 du virus de la grippe A (isolement et purification)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Surveillance sentinelle (MeSH)</term>
<term>Union européenne (MeSH)</term>
<term>Vaccination (MeSH)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Études cas-témoins (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term>
<term>Italy</term>
<term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Case-Control Studies</term>
<term>European Union</term>
<term>Female</term>
<term>Humans</term>
<term>Logistic Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Outcome Assessment, Health Care</term>
<term>Seasons</term>
<term>Sentinel Surveillance</term>
<term>Vaccination</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Espagne</term>
<term>Femelle</term>
<term>France</term>
<term>Humains</term>
<term>Italie</term>
<term>Jeune adulte</term>
<term>Modèles logistiques</term>
<term>Mâle</term>
<term>Saisons</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Surveillance sentinelle</term>
<term>Union européenne</term>
<term>Vaccination</term>
<term>Études cas-témoins</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
<term>Italie</term>
<term>Espagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We conducted a multicentre test negative case control study to estimate the 2013-14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: -1.9;85.4), 39.4% (95%CI: -32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18-64, 65-79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: -145.3;65.4), 25.6% (95%CI: -36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18-64, 65-79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013-14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27065000</PMID>
<DateCompleted><Year>2017</Year>
<Month>10</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>12</Volume>
<Issue>5</Issue>
<PubDate><Year>2016</Year>
<Month>05</Month>
<Day>03</Day>
</PubDate>
</JournalIssue>
<Title>Human vaccines & immunotherapeutics</Title>
<ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
</Journal>
<ArticleTitle>Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.</ArticleTitle>
<Pagination><MedlinePgn>1217-24</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1126013</ELocationID>
<Abstract><AbstractText>We conducted a multicentre test negative case control study to estimate the 2013-14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: -1.9;85.4), 39.4% (95%CI: -32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18-64, 65-79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: -145.3;65.4), 25.6% (95%CI: -36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18-64, 65-79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013-14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rondy</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>a Epicon0063ept , Paris , France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Castilla</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>b Instituto de Salud Pública de Navarra, IdiSNA, CIBER Epidemiología y Salud Pública , Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Launay</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>c Inserm, CIC 1417 and F-CRIN, Innovative clinical research network in vaccinologie (I-REIVAC), Université Paris Descartes; Sorbonne Paris Cité ; Paris , France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Costanzo</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>d Department of Epidemiology and Prevention , IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) , Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ezpeleta</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>e Service of Clinical Microbiology, Complejo Hospitalario de Navarra, IdiSNA , Pamplona , Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Galtier</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>f CHRU de Montpellier, Inserm, CIC 1411 and REIVAC , Montpellier , France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Gaetano Donati</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>g Department of Infectious Disease , Catholic University , Rome , Italy .</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moren</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>a Epicon0063ept , Paris , France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>02</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Hum Vaccin Immunother</MedlineTA>
<NlmUniqueID>101572652</NlmUniqueID>
<ISSNLinking>2164-5515</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005062" MajorTopicYN="N">European Union</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="Y">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Influenza</Keyword>
<Keyword MajorTopicYN="Y">Influenza vaccine</Keyword>
<Keyword MajorTopicYN="Y">case control studies</Keyword>
<Keyword MajorTopicYN="Y">hospital</Keyword>
<Keyword MajorTopicYN="Y">multicentre studies</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>4</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>4</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>10</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27065000</ArticleId>
<ArticleId IdType="pmc">PMC5036960</ArticleId>
<ArticleId IdType="doi">10.1080/21645515.2015.1126013</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14001-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10570188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Apr 19;31(17):2165-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23499601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Psychol Methods. 2006 Jun;11(2):193-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16784338</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Oct 28;28(46):7381-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20851086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2002 Jun 1;168(11):5893-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12023394</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Md State Med J. 1965 Feb;14:61-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14258950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2014 Feb 13;19(6):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24556347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 1989 Apr;102(2):325-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2703026</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2013 Nov 22;342(6161):976-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24264991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Immunol. 2014 Aug;29:38-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24769424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Jun 26;31(30):3104-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23624093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1945-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2014 Apr 24;19(16):20780</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24786262</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Nov 15;29(49):9159-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21840359</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20166072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2013 Aug;13(8):646-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23886322</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(4):e59681</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23565159</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
<li>France</li>
<li>Italie</li>
</country>
</list>
<tree><country name="France"><noRegion><name sortKey="Rondy, M" sort="Rondy, M" uniqKey="Rondy M" first="M" last="Rondy">M. Rondy</name>
</noRegion>
<name sortKey="Galtier, F" sort="Galtier, F" uniqKey="Galtier F" first="F" last="Galtier">F. Galtier</name>
<name sortKey="Launay, O" sort="Launay, O" uniqKey="Launay O" first="O" last="Launay">O. Launay</name>
<name sortKey="Moren, A" sort="Moren, A" uniqKey="Moren A" first="A" last="Moren">A. Moren</name>
</country>
<country name="Espagne"><noRegion><name sortKey="Castilla, J" sort="Castilla, J" uniqKey="Castilla J" first="J" last="Castilla">J. Castilla</name>
</noRegion>
<name sortKey="Ezpeleta, C" sort="Ezpeleta, C" uniqKey="Ezpeleta C" first="C" last="Ezpeleta">C. Ezpeleta</name>
</country>
<country name="Italie"><noRegion><name sortKey="Costanzo, S" sort="Costanzo, S" uniqKey="Costanzo S" first="S" last="Costanzo">S. Costanzo</name>
</noRegion>
<name sortKey="De Gaetano Donati, K" sort="De Gaetano Donati, K" uniqKey="De Gaetano Donati K" first="K" last="De Gaetano Donati">K. De Gaetano Donati</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000134 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000134 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeEspagneV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27065000
   |texte=   Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27065000" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeEspagneV1

This area was generated with Dilib version V0.6.37.
Data generation: Fri Sep 25 11:01:38 2020. Site generation: Sat Feb 13 17:38:04 2021

	Serveur d'exploration sur la grippe en Espagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Espagne

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki